Disease landscape

Myasthenia Gravis clinical trials

Get alerts when Myasthenia Gravis trials change

155 active trials 96 recruiting 36 Phase 3 93 sponsors 30 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 28 of 30 changes on 18 trials

2026-08-15
Primary completion pushed: 2026-06-30 → 2026-12-30
Completion pushed: 2026-06-30 → 2026-12-30
NCT06447597 A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. · Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
2026-08-01
Primary completion pushed: 2026-06-26 → 2027-06-30
NCT05265273 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized… · Janssen Research & Development, LLC · Phase 2/3
2026-08-15
Primary completion pushed: 2025-07-31 → 2026-01-05
Completion pushed: 2026-03-31 → 2026-09-30
NCT04146051 Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) · Cartesian Therapeutics · Phase 2
2026-08-13
Primary endpoint(s) modified
Enrollment increased: 50 → 60 participants
Trial arms changed: 5 → 7
NCT06688435 A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in… · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Phase 1
2026-08-27
Primary completion pushed: 2026-08-10 → 2026-10-05
NCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe… · UCB Biopharma SRL · Phase 2/3
2026-08-13
Enrollment closed, study ongoing
Trial sites reduced: 125 → 116 locations
NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared… · Novartis Pharmaceuticals · Phase 3
2026-08-13
Trial completed
NCT04225871 Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis · UCB Biopharma SRL · Phase 3
2026-08-14
Enrollment reopened
Enrollment increased: 12 → 24 participants
Trial arms changed: 1 → 2
NCT06359041 RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With… · Cabaletta Bio · Phase 1/2
2026-08-04
Enrollment closed, study ongoing
NCT06220201 A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in… · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase 1
2026-08-25
Trial sites expanded: 2 → 7 locations
NCT07463521 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With… · UCB Biopharma SRL · Phase 3
2026-08-01
Enrollment increased: 12 → 14 participants
NCT06149559 A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe… · UCB Biopharma SRL · Phase 2/3
2026-08-22
Trial sites expanded: 24 → 27 locations
NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… · argenx · Phase 2
2026-08-22
Trial sites expanded: 2 → 5 locations
NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… · TG Therapeutics, Inc. · Phase 2
2026-08-13
Trial sites expanded: 145 → 148 locations
NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phase 3
2026-07-31
Trial sites expanded: 84 → 88 locations
NCT07039916 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe… · Immunovant Sciences GmbH · Phase 3
2026-08-04
Trial sites expanded: 3 → 11 locations
NCT07596901 Study of Aritinercept in Patients With Generalized Myasthenia Gravis · Aurinia Pharmaceuticals Inc. · Phase 1/2
2026-07-31
Trial sites expanded: 15 → 24 locations
NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to… · argenx · Phase 2
2026-07-31
Trial sites expanded: 18 → 29 locations
Trial arms changed: 1 → 2
NCT07294170 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy… · argenx
2026-08-11
Completion pushed: 2027-06 → 2028-06
NCT06298552 A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With… · argenx · Phase 3
2026-08-13
Completion pushed: 2027-12-31 → 2028-12-31
NCT07556120 Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) · Shenzhen MagicRNA Biotechnology Co., Ltd · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-12 NCT07761026 AXIS MG Patient Registry Autoimmune Neurology Alliance new
2026-07-21 NCT07717281 PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new
2026-07-20 NCT07714798 Universal STAR-T Cell Injection in Generalized Myasthenia Gravis Daishi Tian new Phase 1
2026-06-30 NCT07676266 A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy The Affiliated Hospital of Qingdao University new Phase 1
2026-06-29 NCT07673744 A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following… TG Therapeutics, Inc. new Phase 2
2026-06-17 NCT07653984 Cohort Study on Neuroimmune Diseases in the Reproductive Age Third Affiliated Hospital, Sun Yat-Sen University new
2026-06-16 NCT07649187 Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG Ming-Hsing Chang new
2026-06-03 NCT07622342 A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis Guangdong Hengrui Pharmaceutical Co., Ltd new Phase 2

Active trials by phase

Early Phase 1
9
Phase 1
15
Phase 1/2
8
Phase 2
12
Phase 2/3
9
Phase 3
27
Phase 4
7
Not charted: 68 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 155

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07246564 Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese… UCB Biopharma SRL Recruiting 2026-05-22
NCT07221838 A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia… Alexion Pharmaceuticals, Inc. Recruiting 2026-04-09
NCT06909214 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With… argenx Recruiting 2026-03-10
NCT07072988 Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia… Centre Hospitalier Universitaire de Nice Recruiting 2025-09-24
NCT06860633 Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod University of Colorado, Denver Recruiting 2025-07-11
NCT06723548 Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis First Affiliated Hospital of Wenzhou Medical University Not Yet Recruiting 2024-12-09
NCT06688253 Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis Rambam Health Care Campus Not Yet Recruiting 2024-11-14
Phase 3
NCT07647510 A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis… Dianthus Therapeutics Recruiting 2026-08-27
NCT07463521 A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With… UCB Biopharma SRL Recruiting 2026-08-24
NCT06463587 Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in… Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Recruiting 2026-08-12
NCT07217587 Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized… Janssen Research & Development, LLC Recruiting 2026-07-31
NCT07039916 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe… Immunovant Sciences GmbH Recruiting 2026-07-30
NCT06744920 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus… Novartis Pharmaceuticals Recruiting 2026-07-29
NCT04951622 A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis Janssen Research & Development, LLC Recruiting 2026-07-27
NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Vor Biopharma Recruiting 2026-06-18
NCT07249632 A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) RemeGen Co., Ltd. Recruiting 2026-04-09
NCT06607627 PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+… Alexion Pharmaceuticals, Inc. Recruiting 2026-04-01
NCT07215949 Zilucoplan for Severe gMG Exacerbations Miriam Freimer Recruiting 2026-02-23
NCT06342544 Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular… Fondation Ophtalmologique Adolphe de Rothschild Recruiting 2026-01-21
NCT05868837 Rituximab EfFicacy IN MyasthEnia Gravis (REFINE) Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting 2025-08-01
NCT06587867 Seronegative Myasthenia Gravis - Efgartigimod IV University Health Network, Toronto Recruiting 2024-09-19
NCT07465289 A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult… UCB Biopharma SRL Not Yet Recruiting 2026-08-25
NCT06540144 An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric… UCB Biopharma SRL Enrolling by Invitation 2026-08-14
NCT06517758 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared… Novartis Pharmaceuticals Active, Not Recruiting 2026-08-12
NCT06298552 A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With… argenx Active, Not Recruiting 2026-08-10
See all 155 active Myasthenia Gravis trials with filters →

Top sponsors by active trials in this area

argenx (12) · Alexion Pharmaceuticals, Inc. (8) · UCB Biopharma SRL (7) · Centre Hospitalier Universitaire de Nice (5) · Tongji Hospital (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (4) · Huashan Hospital (4) · AstraZeneca (3) · Janssen Research & Development, LLC (3) · Novartis Pharmaceuticals (3)

Get alerts when Myasthenia Gravis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free